Gastroenterology
Bile Acid Malabsorption
0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Bile Acid Malabsorption is an early-stage landscape with 0 programs across 1 company. The most active players are AbbVie.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
3
clinical trials
Completed2 · 67%
Terminated1 · 33%
Clinical Trials
Trial Activity
Treatment of Bile Acid Malabsorption With Liraglutide
Completed·—·Phase 4·NCT03955575·52 enrolled
Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease
Terminated·—·Phase 4·NCT01203254·34 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)